A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA

A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA

All the currently used type A botulinum neurotoxins for clinical uses are of subtype A1. We compared the efficacy and safety for the first time head-to-head between a novel botulinum toxin A2NTX prepared from subtype A2 and onabotulinumtoxinA (BOTOX) derived from A1 for post-stroke spasticity. We as...

Full description

Bibliographic Details
Main Authors: Ryuji Kaji, Ai Miyashiro, Nori Sato, Taiki Furumoto, Toshiaki Takeuchi, Ryosuke Miyamoto, Tomoko Kohda, Yuishin Izumi, Shunji Kozaki
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Toxins
Subjects:
botulinum neurotoxin
subtype A2
A2NTX
onabotulinumtoxinA
clinical efficacy
safety
Online Access:https://www.mdpi.com/2072-6651/14/11/739

Internet

https://www.mdpi.com/2072-6651/14/11/739

Similar Items